PolyPid Cash Flow Conversion Efficiency
PolyPid cash flow conversion efficiency. Based on the latest financial reports, PolyPid (PYPD) has a cash flow conversion efficiency ratio of -5.413x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.55 Million) by net assets ($5.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PolyPid (2012–2024)
Cash flow conversion efficiency of PolyPid from 2012 to 2024. This chart illustrates how PolyPid's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for PolyPid for real-time trading data and today's change.
PolyPid Cash Flow Conversion Ratio Explained
PolyPid cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PolyPid Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PolyPid ranked by their cash flow conversion efficiency. Also see PolyPid (PYPD) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cufe Ltd
AU:CUF
|
-0.110x |
|
Manba Finance Ltd
NSE:MANBA
|
-0.483x |
|
BaoMinh Insurance Corp
VN:BMI
|
0.005x |
|
Yatas Yatak ve Yorgan Sanayi Ticaret AS
IS:YATAS
|
0.116x |
|
Dong Yang Pipe
KO:008970
|
-0.111x |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
-0.032x |
|
Asetek A/S
F:A31
|
0.018x |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
-0.191x |
Annual Cash Flow Conversion Efficiency for PolyPid (2012–2024)
The table below shows the annual cash flow conversion efficiency of PolyPid from 2012 to 2024. Review how much free cash does PolyPid generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.68 Million | $-21.96 Million | -2.858x | -134.76% |
| 2023-12-31 | $-2.10 Million | $-17.24 Million | 8.223x | +239.68% |
| 2022-12-31 | $5.83 Million | $-34.32 Million | -5.887x | -553.70% |
| 2021-12-31 | $35.96 Million | $-32.39 Million | -0.901x | -203.50% |
| 2020-12-31 | $72.78 Million | $-21.60 Million | -0.297x | +47.12% |
| 2019-12-31 | $30.93 Million | $-17.36 Million | -0.561x | -374.90% |
| 2018-12-31 | $-81.71 Million | $-16.68 Million | 0.204x | +46.96% |
| 2017-12-31 | $-88.65 Million | $-12.31 Million | 0.139x | -51.54% |
| 2016-12-31 | $-33.96 Million | $-9.73 Million | 0.287x | -98.99% |
| 2015-12-31 | $-231.00K | $-6.57 Million | 28.455x | +9008.17% |
| 2013-12-31 | $-8.06 Million | $-2.52 Million | 0.312x | -23.47% |
| 2012-12-31 | $-4.55 Million | $-1.86 Million | 0.408x | -- |
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients unde… Read more